MetaADEDB 2.0 @ LMMD
Fosinopril
(TVTJZMHAIQQZTL-HREVRLCXSA-M)
Structure
SMILES
CCC(=O)OC(C(C)C)OP(=O)(CC(=O)N1C[C@@H](C[C@H]1C(=O)[O-])C1CCCCC1)CCCCc1ccccc1.[Na+]
Molecular Formula:
C30H45NNaO7P
Molecular Weight:
585.644
Log P:
4.7245
Hydrogen Bond Acceptor:
8
Hydrogen Bond Donor:
0
TPSA:
122.85
CAS Number(s):
88889-14-9; 1217528-56-7
Synonym(s)
1.
Fosinopril
2.
Fosenopril
3.
Dynacil
4.
Fosinil
5.
Fosinopril Sodium
6.
Fosinopril, (1(S*(R*)),2 alpha,4 alpha)-(D-Pro)-Isomer
7.
Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer
8.
Fosinopril, (1(S*(S*)),2 alpha,4 beta)-Isomer
9.
Fosinorm
10.
Fositens
11.
Fozitec
12.
Hiperlex
13.
Monopril
14.
Newace
15.
SQ-28,555
16.
SQ-28555
17.
Staril
18.
Tenso Stop
19.
Tensocardil
20.
SQ 28,555
21.
SQ 28555
22.
SQ28,555
23.
SQ28555
24.
Sodium, Fosinopril
External Link(s)
MeSHD017328
PubChem Compound23681451
ChEBI5164
CHEMBLCHEMBL3188382
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AngioedemaFAERS: 25
Canada Vigilance: 1		Canada Vigilance
US FAERS
2Drug ineffectiveFAERS: 15US FAERS
3WheezingFAERS: 12US FAERS
4NauseaFAERS: 6
Canada Vigilance: 2		Canada Vigilance
US FAERS
5FatigueFAERS: 4US FAERS
6HeadacheFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
7HypersensitivityFAERS: 3US FAERS
8Pharmaceutical product complaintFAERS: 3US FAERS
9Product substitution issueFAERS: 3US FAERS
10PruritusFAERS: 3US FAERS
11AlopeciaFAERS: 2US FAERS
12AphoniaFAERS: 2US FAERS
13AstheniaFAERS: 2US FAERS
14HypotensionFAERS: 2US FAERS
15Lip swellingFAERS: 2US FAERS
16Mouth swellingFAERS: 2US FAERS
17Pharyngolaryngeal PainFAERS: 2US FAERS
18SomnolenceFAERS: 2US FAERS
19StomatitisFAERS: 2US FAERS
20Therapeutic response unexpected with drug substitutionFAERS: 2US FAERS
21UrticariaFAERS: 2US FAERS
22VertigoFAERS: 2US FAERS
23VomitingFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
24Abdominal PainFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
25Abdominal discomfortFAERS: 1US FAERS
26AgeusiaFAERS: 1US FAERS
27AphasiaFAERS: 1US FAERS
28AscitesFAERS: 1US FAERS
29Atrial FibrillationFAERS: 1US FAERS
30BlindnessFAERS: 1US FAERS
31Blood cholesterol increasedFAERS: 1US FAERS
32Blood creatinine increasedFAERS: 1US FAERS
33Blood phosphorus increasedFAERS: 1US FAERS
34Blood potassium increasedFAERS: 1US FAERS
35Blood pressure fluctuationFAERS: 1US FAERS
36Blood pressure inadequately controlledFAERS: 1US FAERS
37Burning sensationFAERS: 1US FAERS
38Cardiac ArrestFAERS: 1US FAERS
39Chest PainFAERS: 1US FAERS
40Chest discomfortFAERS: 1US FAERS
41DizzinessFAERS: 1
Canada Vigilance: 2		Canada Vigilance
US FAERS
42DroolingFAERS: 1US FAERS
43Drug administration errorFAERS: 1US FAERS
44DysgeusiaFAERS: 1US FAERS
45EosinophiliaFAERS: 1US FAERS
46Eye painFAERS: 1US FAERS
47FlushingFAERS: 1US FAERS
48GlossitisFAERS: 1US FAERS
49MalaiseFAERS: 1US FAERS
50Muscle tightnessFAERS: 1US FAERS
51NephrolithiasisFAERS: 1US FAERS
52PainFAERS: 1US FAERS
53PallorFAERS: 1US FAERS
54PancreatitisFAERS: 1US FAERS
55PancytopeniaFAERS: 1US FAERS
56PregnancyFAERS: 1US FAERS
57Product quality issueFAERS: 1US FAERS
58Product taste abnormalFAERS: 1US FAERS
59Productive CoughFAERS: 1US FAERS
60Rash erythematousFAERS: 1US FAERS
61Renal Artery StenosisFAERS: 1US FAERS
62Respiratory distressFAERS: 1US FAERS
63Sexual DysfunctionFAERS: 1US FAERS
64SyncopeFAERS: 1US FAERS
65Therapeutic response unexpectedFAERS: 1US FAERS
66TinnitusFAERS: 1US FAERS
67treatment failureFAERS: 1US FAERS
68Acute kidney injuryCanada Vigilance: 1Canada Vigilance
69ArthralgiaCanada Vigilance: 1Canada Vigilance
70CataractCanada Vigilance: 1Canada Vigilance
71DisorientationCanada Vigilance: 1Canada Vigilance
72MyalgiaCanada Vigilance: 1Canada Vigilance
73Myocardial InfarctionCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120235

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.